Table 5

Outcome variables, measures, psychometric properties and timeline of data collection

Primary outcome
Variable	Measures	Participants	Reliability	Validity	E0	E1	E2	E3
Fear of cancer recurrence severity	FCRI-SF	Patients	Internal consistency, test–retest17 46	Concurrent, convergent, discriminant17 46	✓	✓	✓	✓

Secondary effectiveness outcomes
Variable	Measures	Participants	Reliability	Validity	E0	E1	E2	E3
Demographic information	Demographic questionnaire	Patients	N/A	N/A	✓	–	–	–
Fear of cancer recurrence subscales	FCRI	Patients	Internal consistency, test–retest17 46	Concurrent, convergent, discriminant17 46	✓	✓	✓	✓
Melanoma-related knowledge	Purpose-designed questionnaire	Patients	N/A	N/A	✓	✓	✓	✓
Depression, anxiety and stress	DASS-21	Patients	Internal consistency47–51	Concurrent, convergent, discriminant47–49	✓	✓	✓	✓
Health-related quality of life	AQOL-8D	Patients	Internal consistency, test–retest52–54	Concurrent, convergent, discriminant52 54–56	✓	✓	✓	✓

Secondary implementation outcomes
Variable	Measures	Participants	I1	I2	I3
Acceptability	Acceptability of Intervention Measure	Patients*	–	–	–
	Acceptability of Intervention Measure	Implementation stakeholders	✓	✓	✓
	Semistructured interviews	Patients†	–	–	–
	Expert group discussions	Implementation stakeholders	✓	✓	✓
	Process data	N/A	✓	✓	✓
Appropriateness	Intervention Appropriateness Measure	Patients*	–	–	–
	Intervention Appropriateness Measure	Implementation stakeholders	✓	✓	✓
	Semistructured interviews	Patients†	–	–	–
	Expert group discussions	Implementation stakeholders	✓	✓	✓
Feasibility	Feasibility of Intervention Measure	Implementation stakeholders	✓	✓	✓
Feasibility	Expert group discussions	Implementation stakeholders	✓	✓	✓
Cost	Process data	N/A	✓	✓	✓
Fidelity	Review of telehealth sessions	Implementation stakeholders	–	–	✓
Sustainability	Expert group discussions	Implementation stakeholders	–	✓	✓

E0, baseline; E1, 1-week follow-up; E2, 6-month follow-up; E3, 12-month follow-up.
I1, 3 months pre-implementation; I2, quarterly throughout implementation; I3, 3 months post-implementation.
*Patients will complete the Acceptability of Intervention Measure and Intervention Appropriateness Measure within 1 week of completing their final telehealth session, 6-month and 12-month follow-up.
†Patients will be invited to participate in semistructured interviews within 1 week of completing their final telehealth session.
AQOL-8D, Assessment of Quality of Life–8 Dimensions; DASS-21, Depression, Anxiety and Stress Scales 21-item Short Form; FCRI, Fear of Cancer Recurrence Inventory; FCRI-SF, Fear of Cancer Recurrence Inventory 9-item Short Form; N/A, Not Applicable.